Close-up on a video camera screen, a woman stares into the lens.

Stay up to date on COVID-19. Learn more

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

May 14, 2024

Tecvayli was recommended for reimbursement by the CDA-AMC! 

We are pleased to announce that on April 24th,TECVAYLI (teclistamab) was recommended for reimbursement by the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC)*– the first bispecific antibody for myeloma to be recommended for funding in Canada.   The pERC’s final decision states that contingent on a price reduction, teclistamab should[…]

Learn more

May 14, 2024

A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments

Minimal residual disease (MRD) testing has been recommended as an early endpoint in myeloma clinical trials by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). If the recommendation is adopted by the FDA, it could lead to the accelerated approval of new treatments.  Read more… […]

Learn more

April 23, 2024

Postoperative Radiotherapy Following Spinal Surgery Safe, Effective in Multiple Myeloma 

The current standard of spinal surgery followed by postoperative radiotherapy for osteolytic lesions of multiple myeloma (MM) is safe and associated with a low toxicity profile, according to research published in Strahlentherapie und Onkologie.  Read more…  […]

Learn more

March 19, 2024

Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study 

This study aims to describe the treatment patterns, outcomes, health care utilization and symptom burden of triple class exposed (TCE) relapsed/refractory patents with multiple myeloma (MM) receiving a subsequent line of treatment (LOT).  Read more…  […]

Learn more

February 22, 2024

Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients 

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) is pleased to announce that it has received the first patient sample for its clinical trial monitoring multiple myeloma (“MM”) disease progression in post-treated patients. The study is being conducted in collaboration with McGill University and the Jewish General[…]

Learn more

February 21, 2024

High BMI in Early Adulthood Increases Multiple Myeloma Risk Among Black Women

High body mass index (BMI) in early adulthood associated with increased risk for multiple myeloma (MM) among Black women, according to results published in the British Journal of Cancer.  The incidence of MM is more than 2-times higher for Black persons. Male gender, age, and African ancestry are established MM risk[…]

Learn more
1 2 3 11

Myeloma Canada updates

 

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

May 2, 2024

A round of applause for Martine and her new role! 

It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada.  Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today.[…]

Learn more

April 23, 2024

A Letter To the Decision Makers Whose Decisions Can Impact The Lives Of Canadians Living with Cancer, To Those With The Power to Reshape The Landscape of Cancer Care in Canada 

“Every hour in Canada tells a stark story. Twenty-seven individuals are thrust into the harsh reality of a cancer diagnosis, while ten others succumb to its merciless grip. Each day, 655 Canadians awaken to the daunting challenge ahead, while 238 bid farewell to their loved ones under the weight of[…]

Learn more

April 23, 2024

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action 

“Canada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to[…]

Learn more

April 4, 2024

Myeloma Canada releases 2023 science and research impact report

2023 was a banner year for Myeloma Canada’s science and research funding initiatives. We not only introduced 3 new grants, but we entered into 10 important partnerships, each one focused on advancing essential Canadian myeloma research. We are thrilled to announce that we are currently supporting more than 28 exciting[…]

Learn more

February 22, 2024

IMAGINE CANADA Organization Spotlight: Myeloma Canada 

Established in 2005, Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by multiple myeloma. Their mission is to improve the lives of those affected by this disease by empowering our community through awareness, education, and advocacy programs, and by supporting clinical research to find[…]

Learn more

February 20, 2024

2023 Dr Andrew R Belch MEET Grant for young myeloma investigators 

A total of 8 MEET Grants were awarded in 2023. Click on the links below to view video presentations from select winners and their important work.  Dory Abelman: Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma  “I am profoundly[…]

Learn more
1 2 3 17